TRACON Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Recent Corporate Highlights
- In October, we entered into a Common Stock Purchase Agreement (the “2019 Purchase Agreement”) of up to $15.0 million with Aspire Capital Fund, LLC (“Aspire Capital”) which has committed to purchase up to $15.0 million of shares of the Company’s common stock at TRACON’s request from time to time during the 30-month period of the purchase agreement and at prices based on the market price at the time of each sale. Upon entering into the 2019 Purchase Agreement, the prior Common Stock Purchase Agreement executed in
March 2017was terminated.
- In November, we agreed with Janssen that the more than 70 currently enrolled patients in the Phase 1/2 trial of TRC253 are sufficient to determine the risk-benefit profile of the drug in three cohorts of metastatic castrate resistant prostate cancer patients: those with a F877L mutation, those with another undisclosed androgen receptor point mutation, and those with another basis for resistance to Xtandi or Erleada. While not mature, the available Phase 2 data indicate a lower than expected initial response rate and prevalence of the F877L mutation.
“We are pleased to have entered into another transaction with
Expected Upcoming Milestones
- Top-line data, including the primary endpoint of mean change in best corrected visual acuity at six months, from the randomized Phase 2
AVANTEtrial of DE-122 in patients with wet AMD are expected in the first half of 2020. In this trial DE-122 is being combined with Lucentis and being compared with Lucentis single agent treatment.
- The Phase 2 POC data from the Phase 1/2 clinical trial of TRC253 in metastatic castrate resistant prostate cancer is now expected in the first half of 2020, whereupon Janssen have an exclusive option to reacquire full rights to TRC253 for an opt-in payment of $45 million to TRACON, and obligations to pay regulatory and commercialization milestones totaling up to
$137.5 millionupon achievement of specified events, in addition to a low single-digit royalty on net sales. If Janssen does not opt in TRACON can advance TRC253 independently, in which case TRACON would owe Janssen up to $45 millionupon achievement of specified events, in addition to a low single-digit royalty on net sales.
- Top line data for the Phase 1 dose escalation study of TJ004309, a CD73 antibody, as a single agent and in combination with Tecentriq, a marketed PD-L1 antibody being supplied by
Roche, is expected in the second half of 2020. We are developing TJ004309 in collaboration with I-Mab Biopharma.
- Nomination and IND filing of the initial bispecific antibody (BsAb) from the I-Mab pipeline is expected in the second half of 2020. The I-Mab pipeline includes PD-L1 x IL-7, PD-L1 x CD47, PD-L1 x CD73, PD-L1 x B7-H3, and PD-L1 x 4-1BB antibodies. TRACON and I-Mab previously entered into a cost-sharing product development collaboration whereby TRACON will be responsible for the regulatory and clinical development of up to five of the BsAbs in
North Americaand Europe, with the majority of the development effort expected to occur in the U.S. TRACON will bear the costs of early phases of clinical trials and I-Mab will share the costs for more advanced development stages and commercialization. TRACON will share the North Americarights of any selected BaAbs with I-Mab for each collaborative program and retains an opt-in right to in-license the BsAbs from I-Mab ex-greater China.
Third Quarter 2019 Financial Results
- Cash, cash equivalents and short-term investments were
$19.1 millionat September 30, 2019compared to $39.1 millionat December 31, 2018. We expect our current cash, cash equivalents and short-term investments to fund operations into the third quarter of 2020.
- Research and development expenses for the third quarter of 2019 were
$3.1 millioncompared to $7.0 millionfor the third quarter of 2018. The decrease was primarily attributable to lower manufacturing expenses and clinical trial expenses due to the discontinuation of the TRC105 program.
- General and administrative expenses for the third quarter of 2019 were
$2.0 millioncompared to $2.1 millionfor the third quarter of 2018.
- Net loss for the third quarter of 2019 was
$5.2 millioncompared to $9.1 millionfor the third quarter of 2018.
Investor Conference Call
The Company will hold a conference call today at
After the live webcast, a replay will remain available on TRACON’s website for 60 days.
About DE-122 (carotuximab)
DE-122, an ophthalmic formulation of carotuximab, is active in preclinical choroidal neovascularization (CNV) models and designed to enhance the effect of approved VEGF inhibitors used to treat wet AMD. DE-122 is being investigated in the Phase 2 randomized
TRC253 is a novel, orally bioavailable small molecule drug that is a potent, high affinity competitive inhibitor of the androgen receptor (AR) and AR mutations, including the F877L mutation. The AR F877L mutation results in an alteration in the AR ligand binding domain that confers resistance to therapies for prostate cancer. Therapies targeting the AR have demonstrated clinical efficacy by extending time to disease progression, and in some cases, the survival of patients with metastatic castration-resistant prostate cancer. However, resistance to these agents is often observed and several molecular mechanisms of resistance have been identified, including gene amplification, overexpression, alternative splicing, and point mutation of the AR. TRC253 is currently being studied in a Phase 1/2 clinical trial in prostate cancer. For more information about the clinical trial, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php
TJ004309 is a novel, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is highly immunosuppressive. TJ004309 is currently being studied in a Phase 1 trial to assess safety and preliminary efficacy as a single agent and when combined with the PD-L1 checkpoint inhibitor Tecentriq in patients with advanced solid tumors.
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: DE-122, the ophthalmic formulation of carotuximab, an endoglin antibody that is being developed for patients with wet AMD through a license to
Statements made in this press release regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding TRACON's plans to further develop product candidates, expectations regarding the timing and scope of clinical trials and availability of clinical data, expected development milestones, estimated cash runway, potential access to future capital, potential utility of product candidates, potential events under collaboration and license agreements, and TRACON’s business development strategy and goals to enter into additional collaborations. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development; whether TRACON or others will be able to complete or initiate clinical trials on TRACON’s expected timelines, if at all; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; the fact that TRACON has limited control over whether or when third party collaborators complete on-going trials or initiate additional trials of TRACON’s product candidates; the fact that TRACON’s collaboration agreements are subject to early termination; whether TRACON will be able to enter into additional collaboration agreements on favorable terms or at all; whether and when any bispecific antibodies are developed under TRACON’s collaboration with I-Mab; potential changes in regulatory requirements in
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
|Three Months Ended
|Nine Months Ended
|Research and development||3,056||6,976||12,617||24,529|
|General and administrative||2,025||2,107||5,867||5,480|
|Total operating expenses||5,081||9,083||18,484||30,009|
|Loss from operations||(5,081||)||(9,083||)||(18,484||)||(27,009||)|
|Total other income (expense)||(118||)||(2||)||(254||)||(194||)|
|Net loss per share, basic and diluted||$||(0.17||)||$||(0.30||)||$||(0.63||)||$||(1.05||)|
|Weighted‑average common shares outstanding, basic and diluted||29,937,457||29,837,486||29,919,776||25,962,237|
Condensed Consolidated Balance Sheets
|September 30,||December 31,|
|Cash and cash equivalents||$||19,053||$||25,136|
|Prepaid and other assets||1,217||1,499|
|Total current assets||20,270||40,603|
|Property and equipment, net||27||45|
|Liabilities and Stockholders’ Equity|
|Accounts payable and accrued expenses||$||9,204||$||10,947|
|Accrued compensation and related expenses||1,056||1,464|
|Long‑term debt, current portion||2,570||1,084|
|Total current liabilities||12,830||13,495|
|Other long-term liabilities||945||368|
|Long‑term debt, less current portion||3,402||5,343|
|Commitments and contingencies|
|Additional paid‑in capital||162,403||161,072|
|Total stockholders’ equity||4,035||21,442|
|Total liabilities and stockholders’ equity||$||21,212||$||40,648|
|Company Contact:||Investor Contact:|
|Mark Wiggins||Andrew McDonald|
|Chief Business Officer||LifeSci Advisors LLC|
Source: TRACON Pharmaceuticals, Inc.